This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Competitive effects of Cochlear-Oticon Medical deal assessed by UK CMA

( January 20, 2023, 12:31 GMT | Official Statement) -- MLex Summary: The competitive effects of Cochlear’s proposed acquisition of Oticon Medical, the hearing-implant division of Demant, will be assessed by the Competition and Markets Authority during its in-depth investigation of the deal, the UK regulator has said. Previously, the CMA said the proposed deal would result in the merged company having a 90-100 percent share of the UK market for bone-conduction solutions, and that the deal would result in the elimination of Oticon Medical, the strongest competitor in this segment. This could lead to reduced innovation, higher prices or less choice for hospitals and their patients, the CMA said.Statement follows. Issues statement is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections